The proportion of individuals with a PD-L1 TPS of ≥1% was 34%, which is similar to values determined with the same monoclonal antibody (clone 28–8) for HNC and melanoma in clinical trials [22, 23]. The gene discussed is CD274; the disease is melanoma.